Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 87Breast Neoplasms 49Prostatic Neoplasms 42Squamous Cell Carcinoma of Head and Neck 34Lung Neoplasms 24Neoplasms 19Stomach Neoplasms 18Head and Neck Neoplasms 17Neoplasm Metastasis 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Urinary Bladder Neoplasms 13Carcinoma, Transitional Cell 11Triple Negative Breast Neoplasms 10Ovarian Neoplasms 8Endometrial Neoplasms 8Carcinoma, Squamous Cell 8Adenocarcinoma 8HER2-positive Breast Cancer 7Non-Muscle Invasive Bladder Neoplasms 6Melanoma 6Carcinoma 6Small Cell Lung Carcinoma 5Prostatic Neoplasms, Castration-Resistant 5Nasopharyngeal Carcinoma 5Esophageal Neoplasms 5Uterine Cervical Neoplasms 4Sarcoma 4Oropharyngeal Neoplasms 4Fallopian Tube Neoplasms 4Esophageal Squamous Cell Carcinoma 4

Interventions

Pluvicto 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone Naive Prostate Cancer × Docetaxel × 1 year × Clear all
NCT04343885 2025-07-11

UpFrontPSMA

Peter MacCallum Cancer Centre, Australia

Phase 2 Active not recruiting
130 enrolled
Genitourinary

Metastatic Hormone Naive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡